Chronic Kidney Disease Implications in Type 2 Diabetes Management

Chronic kidney disease (CKD) represents one of the most serious microvascular complications of type 2 diabetes mellitus, affecting renal structure and function through mechanisms that include glomerular hyperfiltration, oxidative stress and low-grade inflammation. Progressive decline in renal function compounds cardiovascular risk, necessitates adjustment of glycaemic targets and demands careful selection and dosing of antihyperglycaemic and antihypertensive therapies. Early detection through regular estimation of glomerular filtration rate and assessment of urinary albumin excretion enables risk stratification, facilitates renoprotective interventions and may slow progression towards end-stage kidney disease. Integrating multidisciplinary care—encompassing tight control of blood pressure, optimisation of glycaemic control, lipid management and lifestyle modification—reduces both renal and cardiovascular morbidity. Recent therapeutic advances, notably the introduction of sodium–glucose cotransporter 2 inhibitors and non-steroidal mineralocorticoid receptor antagonists, offer significant renoprotection beyond glucose lowering. Globally, disparities in access to screening and treatment underscore the need for tailored public health strategies, especially in regions with high diabetes prevalence. In clinical practice, CKD in people with type 2 diabetes demands vigilant monitoring, timely therapeutic adaptation and close collaboration between diabetologists and nephrologists to achieve optimal outcomes.

Research from Nature Portfolio

Analyses of a large Southeast Asian diabetes registry have revealed that over half of patients with type 2 diabetes exhibit evidence of diabetic kidney disease, defined by reduced filtration rate and/or albuminuria. Age, duration of diabetes, suboptimal glycaemic control and hypertension emerged as the most significant risk factors, highlighting the urgent need for integrated monitoring programmes in primary care. A complementary study in a northern Thai cohort of more than a thousand primary-care patients reported a CKD prevalence of nearly one quarter, with higher stages seen in older individuals and those with poor glycaemic indices. The work underscores that early identification of albuminuria and timely initiation of renin–angiotensin system inhibitors can modify disease trajectory, improving long-term renal and cardiovascular prognosis.

Chronic Kidney Disease Implications in Type 2 Diabetes Management publication trend

The graph below shows the total number of articles in chronic kidney disease implications in type 2 diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

Estimated glomerular filtration rate (eGFR): A calculated measure of kidney function based on serum creatinine, age, sex and body size.

Albuminuria: The presence of albumin in urine, indicating increased glomerular permeability and early renal damage.

Renin–angiotensin system inhibitors: Medications that block angiotensin-converting enzyme or angiotensin receptors to reduce intraglomerular pressure and proteinuria.

Sodium–glucose cotransporter 2 inhibitors (SGLT2i): Oral agents that lower blood glucose by promoting renal glucose excretion and confer additional cardiovascular and renal benefits.

References

1. Prevalence of diabetic kidney disease and the associated factors among patients with type 2 diabetes in a multi-ethnic Asian country. Scientific Reports (2024).
2. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetology & Metabolic Syndrome (2023).
3. Incidence and predictors of chronic kidney disease among patients with diabetes treated at governmental hospitals of Harari Region, eastern Ethiopia, 2022. Frontiers in Public Health (2024).
4. Prevalence and Risk Factors of Chronic Kidney Disease among Type 2 Diabetes Patients: A Cross-Sectional Study in Primary Care Practice. Scientific Reports (2020).